Welcome to our dedicated page for Zomedica news (Ticker: ZOM), a resource for investors and traders seeking the latest updates and insights on Zomedica stock.
Zomedica Corp. develops and commercializes animal-health diagnostic and therapeutic device products for equine and companion-animal care. Company news commonly covers expansion of the TRUFORMA point-of-care diagnostic menu, including equine endocrine and reproductive assays, and updates for therapeutic brands such as PulseVet, Assisi, Calmer Canine, EquiLoop, and VETIGEL.
Recurring updates also address product launches, veterinary monitoring technology such as the VETGuardian Zero Touch monitor, distribution arrangements for international markets, investor webinars, financial results, and the development-services segment tied to engineering, contract manufacturing, and intellectual-property licensing.
Zomedica Corp. (NYSE American:ZOM) reported its first quarter 2024 financial results, showcasing a 14% revenue increase to $6.3 million, with a 66% gross margin and $91 million in liquidity. The company's revenue growth was driven by both the Therapeutic Devices and Diagnostics segments, with consumable revenues reaching $4.0 million and capital revenues hitting $2.2 million. Zomedica's CEO, Larry Heaton, expressed optimism for future growth opportunities as the company continues to expand its portfolio and commercial organization.
Zomedica Corp. (NYSE American:ZOM) will be presenting at the EF Hutton Annual Global Conference on May 15, 2024. The Chief Executive Officer, Larry Heaton, will be presenting and holding investor meetings. Zomedica is a veterinary health company providing diagnostics and products for animals.
Zomedica Corp. received CE certification for its VetGuardian(R) remote contactless monitoring system, opening doors for European expansion in the $4 billion vet services market. The system utilizes radar technology for stress-free and efficient patient monitoring, enhancing operational workflow and outcomes. This milestone allows Zomedica to tap into the growing demand from veterinarians worldwide, driving innovation in the veterinary health sector.
Zomedica Corp. strengthens its market position with the issuance of three new patents for its TRUFORMA diagnostic platform. The patents cover innovative design and functionality improvements, enhancing the system's ability to detect a wide array of health conditions in horses and companion animals. With a total of 65 U.S. patents, 123 international patents, and 33 U.S. and 98 foreign trademarks, Zomedica solidifies its intellectual property portfolio and market presence in the veterinary health industry.
Zomedica Corp will report its first quarter 2024 financial results on May 9th, 2024, providing insights into its operational and financial performance. The company, focused on veterinary health products, will host a conference call and webcast to discuss the highlights of the quarter.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.